Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 represents -C_{1-6} alkyl-O-C_{1-6} alkyl, -C_{3-8} cycloalkyl, aryl, heterocyclyl, heteroaryl, -C_{1-6} alkyl-aryl, -C_{1-6} alkyl-heteroaryl, -C_{1-6} alkyl-heterocyclyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl,- heteroaryl-X-aryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-heterocyclyl, -heterocyclyl-X-aryl, -heterocyclyl-X-heteroaryl, or -heterocyclyl-X-heterocyclyl,

wherein said C_{1-6} alkyl, C_{3-8} cycloalkyl, aryl, heteroaryl, and heterocyclyl groups of R^1 may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC_{1-6} alkyl, polyhaloC_{1-6} alkyl, haloC_{1-6} alkoxy, polyhaloC_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, or a group $NR^{15}R^{16}$, -$CONR^{15}R^{16}$, -$NR^{15}COR^{16}$, -$NR^{15}SO_2R^{16}$, and -$SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen or C_{1-6} alkyl or together form a heterocyclic ring;

X represents a bond, O, CO, OCH_2, CH_2O, or SO_2;

Z represents CO, $CONR^{10}$, or SO_2;

R^{10} represents hydrogen, C_{1-6} alkyl, -C_{3-8} cycloalkyl, aryl, heterocyclyl, or heteroaryl;

$\overline{\text{----}}$ represents a single or a double bond;

m and n independently represent 0, 1, or 2;

R^2 represents hydrogen, C_{1-6} alkyl, or C_{1-6} alkoxy;

R^3 represents halogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, cyano, amino, $-COC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, or trifluoromethyl;

R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):



(i)

wherein q is ~~2,~~ 3, or 4;

$-NR^{11}R^{12}$ represents a heterocyclic group optionally substituted by one or more R^{17} groups;

R^{13} represents C_{1-6} alkyl, C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-C_{1-6} alkoxy, $-C_{1-6}$ alkyl-C_{3-8} cycloalkyl;

R^{14} and R^{17} independently represent halogen, C_{1-6} alkyl, haloalkyl, OH, or C_{1-6} alkoxy;

f is 0 or 1;

g is 1 or 2

k is 0, 1, or 2

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound as defined in claim 1 wherein R^1 represents:

-aryl optionally substituted by 1 or 2 halogen, haloC_{1-6} alkyl, cyano or SO_2Me groups;

-aryl-X-heterocyclyl;

-heteroaryl optionally substituted by 1 or 2 haloC_{1-6} alkyl or cyano groups;

-heterocyclyl optionally substituted by 1 or 2 oxo groups; or

$-C_{1-6}$ alkyl-O-C_{1-6} alkyl.

3. (Previously Presented) A compound as defined in claim 2 wherein R^1 represents tetrahydropyranyl, 4-cyanophenyl, 2-cyanopyridin-3-yl, or 2-trifluoromethylpyridin-3-yl.

4. (Original) A compound as defined in claim 3 wherein R^1 represents 4-cyanophenyl.

5. (Previously Presented) A compound as defined in claim 1 wherein X and Z both represent CO.

6. (Previously Presented) A compound as defined in claim 1 wherein $\overline{----}$ represents a single bond.

7. (Previously Presented) A compound as defined in claim 1 wherein m and n both represent 0.

8. (Previously Presented) A compound as defined in claim 1 wherein R^4 represents -$(CH_2)_q$-$NR^{11}R^{12}$, q represents 3 and -$NR^{11}R^{12}$ represents N-piperidinyl or N-pyrrolidinyl optionally substituted by 1 or 2 C_{1-6} alkyl groups; or wherein R^4 represents a group of formula (i) wherein f and k both represent 0, g represents 2, and R^{13} represents C_{1-6} alkyl or C_{3-8} cycloalkyl.

9. (Original) A compound as defined in claim 8 wherein R^4 represents a group of formula (i) wherein f and k both represent 0, g represents 2 and R^{13} represents i-propyl.

10. (Original) A compound as defined in claim 1 which is:
4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)piperidine;
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}benzonitrile;
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}pyridine;
4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-{[4-(1-pyrrolidinylcarbonyl)phenyl] carbonyl} piperidine;
1-{[4-(Methylsulfonyl)phenyl]carbonyl}-4-(4-{[3-(1-piperidinyl) propyl] oxy} phenyl) piperidine;
1-[(4-Fluorophenyl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperidine;
3-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}pyridine;
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}morpholine;
1-(1-Piperidinylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperidine;
4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-(1-pyrrolidinylcarbonyl)piperidine;
1-(4-Fluoro-phenyl)-1-{4-[4-(1- isopropyl-piperidin-4-yloxy)-phenyl]-piperidin-1-yl}-methanone;
1-(1-Methylethyl)-4-{[4-(1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}-4-piperidinyl)phenyl]oxy}piperidine;
1-(1-Methylethyl)-4-({4-[1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-4-piperidinyl] phenyl}oxy)piperidine;
1-(1-Methylethyl)-4-{[4-(1-{[4-(methylsulfonyl)phenyl]carbonyl}-4-piperidinyl)phenyl]oxy}piperidine;
1-(1-Methylethyl)-4-[(4-{1-[3-(methyloxy)propanoyl]-4-piperidinyl} phenyl)oxy]piperidine;
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl}pyridine;

3-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl}pyridine;
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl]carbonyl} morpholine;
1-(1-Azetidinylcarbonyl)-4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl) piperidine;
1-(1-Methylethyl)-4-({4-[1-(1-pyrrolidinylcarbonyl)-4-piperidinyl] phenyl}oxy)piperidine;
1-(1-Methylethyl)-4-({4-[1-(1-piperidinylcarbonyl)-4-piperidinyl]phenyl}oxy)piperidine;
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl} thiomorpholine 1,1-dioxide;
4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy] phenyl}-1-piperidinyl)carbonyl] benzonitrile;
1-Cyclobutyl-4-[(4-{1-[(4-fluorophenyl) carbonyl]-4-piperidinyl}phenyl) oxy] piperidine;
1-Cyclobutyl-4-{[4-(1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}-4-piperidinyl)phenyl]oxy}piperidine;
1-Cyclobutyl-4-[(4-{1-[3-(methyloxy) propanoyl]-4-piperidinyl} phenyl)oxy] piperidine;
4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy] phenyl}-1-piperidinyl)carbonyl]pyridine;
3-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperidinyl)carbonyl]pyridine;
4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperidinyl)carbonyl]morpholine;
1-[(4-Fluorophenyl)carbonyl]-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1,2,3,6-tetrahydropyridine;
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy} phenyl)-3,6-dihydro-1(2*H*)-pyridinyl] carbonyl} benzonitrile;
4-(4-{[3-(1-Piperidinyl)propyl] oxy}phenyl)-1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}-1,2,3,6-tetrahydropyridine;
4-(4-{[3-(1-Piperidinyl)propyl] oxy} phenyl)-1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;
1-{[4-(Methylsulfonyl)phenyl]carbonyl}-4-(4-{[3-(1-piperidinyl)propyl]oxy} phenyl) -1,2,3,6-tetrahydropyridine;
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-3,6-dihydro-1(2*H*)-pyridinyl]carbonyl} morpholine;
1-(1-Piperidinylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1,2,3,6-tetrahydropyridine;
4-(4-{[3-(1-Piperidinyl)propyl]oxy} phenyl)-1-(1-pyrrolidinylcarbonyl)-1,2,3,6-tetrahydropyridine;
1-[(4-Fluorophenyl)carbonyl]-4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1,2,3,6-tetrahydropyridine;

4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2*H*)-pyridinyl]carbonyl}benzonitrile;
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}-1,2,3,6-tetrahydropyridine;
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy} phenyl)-1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-{[4-(methylsulfonyl)phenyl]carbonyl}-1,2,3,6-tetrahydropyridine;
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2*H*)-pyridinyl]carbonyl}pyridine;
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2*H*)-pyridinyl]carbonyl}morpholine;
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-(1-piperidinylcarbonyl)-1,2,3,6-tetrahydropyridine;
4-(4-{[1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-(1-pyrrolidinyl carbonyl)-1,2,3,6-tetrahydropyridine;
4-({4-[4-({3-[(2*R*)-2-Methyl-1-pyrrolidinyl]propyl}oxy)phenyl]-1-piperidinyl} carbonyl)benzonitrile;
4-[4-({3-[(2*R*)-2-Methyl-1-pyrrolidinyl]propyl}oxy)phenyl]-1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)piperidine;
4-[4-({3-[(2*R*,5*R*)-2,5-Dimethyl-1-pyrrolidinyl]propyl}oxy)phenyl]-1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)piperidine;
2-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl} pyrazine;
3-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl} benzonitrile;
1-(1-Methylethyl)-4-{[4-(1-{[4-(trifluoromethyl)phenyl]carbonyl}-4-piperidinyl)phenyl]oxy}piperidine;
6-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl} quinoxaline;
or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) A compound as defined in claim 1 which is:
5-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl}-2-pyridinecarbonitrile;
5-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl}-2-(trifluoromethyl)pyridine;

or a pharmaceutically acceptable salt thereof.

12. (Original) A compound as defined in claim 1 which is: 4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl} benzonitrile or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

14-16. (Cancelled).

17. (Currently Amended) A method of treatment of a neurological ~~diseases~~ disease selected from Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychiatric disorders including schizophrenia, attention deficit hypereactivity disorder, depression and addiction, which comprises administering to a human ~~host~~ in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.

18. (Cancelled).

19. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) preparing a compound of formula (I) wherein Z represents CO which comprises reacting a compound of formula (II)



(II)

or an optionally activated or protected derivative thereof, wherein ---- , R^2, R^3, R^4, m and n are as defined in claim 1, with a compound of formula R^1-CO-L^1, wherein R^1 is as defined in claim 1and L^1 represents a suitable leaving group such as a suitable halogen atom, or a hydroxyl group; or

(b) preparing a compound of formula (I) wherein Z represents SO_2 which comprises reacting a compound of formula (II), with a compound of formula R^1-SO_2-L^2, wherein R^1 is as defined in claim 1and L^2 represents a suitable leaving group, such as a suitable halogen atom (eg. chlorine); or

(c) preparing a compound of formula (I) wherein Z represents CONH which comprises reacting a compound of formula (II), with a compound of formula R^1-N=C=O, wherein R^1 is as defined in claim 1; or

(d) preparing a compound of formula (I) wherein Z represents $CONR^{10}$ which comprises reacting a compound of formula (II), with a compound of formula $R^1R^{10}N$-L^3, wherein R^1 and R^{10} are as defined in claim 1 and L^3 represents hydrogen or COCl; or

(e) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter

(f) interconversion to other compounds of formula (I).

20. (New) A method according to claim 17 in which the neurological disease is Alzheimer's disease.

21. (New) A method according to claim 17 in which the psychiatric disorder is schizophrenia associated cognitive deficit.